Showing 1711-1720 of 1922 results for "".
- Effort To ‘End Blindness’ Marks Milestone With Leading Scientists Recognized For Pioneering Workhttps://modernod.com/news/effort-to-end-blindness-marks-milestone-with-leading-scientists-recognized-for-pioneering-work/2478623/End Blindness 2020, a joint effort by leading scientists and figures from the worlds of business, politics, culture, art, music and entertainment to rid the world of blindness, is about to mark a milestone. On December 14, 2020, 13 scientists will share
- American Academy of Ophthalmology Leads Global Initiative to Address Worldwide Myopia Epidemichttps://modernod.com/news/american-academy-of-ophthalmology-leads-global-initiative-to-address-worldwide-myopia-epidemic/2478535/The number of Americans who are nearsighted has nearly doubled over the last 50 years to about 41.6 percent. This upward trend is evident in nearly every corner of the world, but nowhere near as dramatic as in East and Southeast Asia, where 80 to 90 percent of chi
- Low Vision Resources and Rehabilitation for Retinal Degeneration Patients: A Webinar to Discuss Critical Needs and Opportunitieshttps://modernod.com/news/low-vision-resources-and-rehabilitation-for-retinal-degeneration-patients-a-webinar-to-discuss-critical-needs-and-opportunities/2478431/The Foundation Fighting Blindness is hosting a low vision webinar to inform eye care professionals about the many opportunities to greatly enhance the quality of life, and provide hope, for their retinal disease patients. The interactive webinar is appropriate for all eye care professional
- Concerns Over Surgical Waste Are Clouding Future of Single-Use Device Markethttps://modernod.com/news/concerns-over-surgical-waste-are-clouding-future-of-single-use-device-market/2478423/The global single-use surgical device market has shown steady growth over several decades, reaching a peak of $3.4 billion in 2019, but growing concerns over the amount of waste created by disposable surgical devices have raised questions about future growth prospects, according to a Market Scope
- CooperVision Presents 6-Year Data from MiSight 1 Day Studyhttps://modernod.com/news/coopervision-presents-6-year-data-from-misight-1-day-study/2478397/CooperVision is reporting the latest findings from its landmark MiSight 1 day clinical study, providing new insights about myopia management and the efficacy of the specially designed contact lens. Among many powerful outcomes are that nearly one in four children’s eyes originally fit with MiSigh
- CMS Alerts Providers to Changes to Medicare Advance Loan Repayments, Giving Hospitals More Timehttps://modernod.com/news/cms-alerts-providers-to-changes-to-medicare-advance-loan-repayments-giving-hospitals-more-time/2478399/The Trump administration laid out more information Thursday about how providers facing financial hardship can get help with repaying loans they received through the Medicare Accelerated and Advance Payments Program, according to a FierceHealthcare
- Celebrities, Athletes and Authors Read Bedtime Stories on World Sight Dayhttps://modernod.com/news/celebrities-athletes-and-authors-read-bedtime-stories-on-world-sight-day/2478366/On World Sight Day, October 8, numerous celebrities, athletes and authors will read Bedtime Stories to children globally to launch the free digital children’s book “Through the Looking Glasses: Stories About Seeing Clearly.” Global vision organizations OneSight, Clearly and IAP
- Inovio’s COVID-19 Vaccine Candidate INO-4800 Hit by FDA Partial Holdhttps://modernod.com/news/inovios-covid-19-vaccine-candidate-ino-4800-hit-by-fda-partial-hold/2478341/Inovio Pharmaceuticals said that the FDA placed a partial clinical hold on a planned phase 2/3 study of its COVID-19 vaccine candidate INO-4800. According to Inovio, the FDA has “additional questions” about the planned trial, including the CELLECTRA 2000 delivery device to be
- Lumenis Unveils Its First US Tour With Launch Of Mobile Outdoor Tradeshow Boothhttps://modernod.com/news/lumenis-unveils-its-first-us-tour-with-launch-of-mobile-outdoor-tradeshow-booth/2478311/Lumenis has announced its first mobile tour (LuMobile), September 28 through April 2021. The company will bring its flagship devices to practitioners in a safe environment aboard the new LuMobile outdoor tradeshow exhibit. The 20-city mo
- Oxford Says AstraZeneca Trial Illnesses May Not Be Linked to COVID-19 Vaccinehttps://modernod.com/news/oxford-says-astrazeneca-trial-illnesses-may-not-be-linked-to-covid-19-vaccine/2478290/Neurological symptoms developed by some volunteers in a trial testing AstraZeneca’s COVID-19 vaccine candidate AZD1222 either probably did not come about as a result of the vaccine, or there is not enough evidence to say one way or the other, according to the University of Oxford. The discl